Overview

A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCC

Status:
Not yet recruiting

Trial end date:
2023-01-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to observe and evaluate the efficacy and safety of Sintilimab for Consolidation Therapy After Radical Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma

Phase:

Phase 2

Details

Lead Sponsor:

The First Affiliated Hospital of Zhengzhou University

Treatments:

Capecitabine
Cisplatin